Optical Genome Mapping in MDS and AML as tool for structural variant profiling—comment and data update on Yang et al.: “High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance”
Open Access
- 24 November 2022
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 37 (1) , 248-249
Abstract
No abstract availableKeywords
Funding Information
- Female Clinician Scientist program of Ruhr-Univeristy Bochum, German, Grant number K147-21
This publication has 6 references indexed in Scilit:
- Broad genomic workup including optical genome mapping uncovers a DDX3X: MLLT10 gene fusion in acute myeloid leukemiaFrontiers in Oncology, 2022
- High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significanceLeukemia, 2022
- Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approachAmerican Journal of Hematology, 2022
- Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in AML/MDS patientsInternational Journal of Cancer, 2022
- The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic LeukemiaCancers, 2021
- Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mappingThe American Journal of Human Genetics, 2021